Christopher Coss

Associate Professor

Ohio State University

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Christopher Coss is an Associate Professor at The Ohio State University in the United States. His research primarily focuses on the development and synthesis of novel pharmaceutical agents, particularly in the areas of cancer treatment, receptor modulation, and pharmacokinetic modeling. His recent publications include works on androgen receptor splice variants, estrogen receptor agonists, and the exploration of natural product structures as therapeutic leads.

Articles (13)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (10)

Alessandra S. Eustáquio

UNITED STATES

View details

UNITED STATES

View details

L. Harinantenaina Rakotondraibe

Associate Professor

Ohio State University

UNITED STATES

View details

James Fuchs

Professor

Ohio State University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christopher Coss

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Valine–Niclosamide for Treatment of Androgen Receptor Splice Variant-Positive Hepatocellular Carcinoma

Translational Pharmacokinetic-Pharmacodynamic Modeling of a Novel Oral Dihydroorotate Dehydrogenase (DHODH) Inhibitor, HOSU-53 (JBZ-001)

An Estrogen Receptor β Agonist with AR Antagonist Activity from a Modern Asymmetric De Novo Steroid Synthesis

Merging Natural Product Structures with Pharmaceutical Leads: Unnatural Enantiomers of Estranes as Glucocorticoid Receptor Modulators That Suppress TNF-α and IL-6 Release

Function-Oriented Synthesis of Pentacyclic Triterpenoids and Discovery of an ent-Estrane as a Natural Product-Inspired Androgen Receptor Antagonist

Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors

Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models

Discovery of Anticancer Agents of Diverse Natural Origin.

Constitutively Active Androgen Receptor in Hepatocellular Carcinoma

The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer

Structure-Activity Relationship of <i>para</i>-Carborane Selective Estrogen Receptor β Agonists.

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing

Collaborators (10)

Alessandra S. Eustáquio

Mitch Phelps

Zobeida Cruz-Monserrate

Glenn Micalizio

Moray Campbell

Erinn Hade

A. Douglas Kinghorn

Katharine A. Collier

L. Harinantenaina Rakotondraibe

James Fuchs

Make your next move.